Literature DB >> 24652737

Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases.

Danilo Fintini1, Graziano Grugni, Claudia Brufani, Sarah Bocchini, Marco Cappa, Antonino Crinò.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24652737     DOI： 10.2337/dc13-2575

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  16 in total

Review 1.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

Review 2.  Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome.

Authors:  Antonino Crinò; Graziano Grugni
Journal:  Curr Diab Rep       Date:  2020-02-06       Impact factor: 4.810

Review 3.  Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.

Authors:  Giovanna Muscogiuri; Gloria Formoso; Gabriella Pugliese; Rosaria Maddalena Ruggeri; Elisabetta Scarano; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

Review 4.  Prader-Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach.

Authors:  Silvia Savastano; Giovanna Muscogiuri; Luigi Barrea; Claudia Vetrani; Danilo Fintini; Giulia de Alteriis; Filippo Maria Panfili; Sarah Bocchini; Ludovica Verde; Annamaria Colao
Journal:  Curr Obes Rep       Date:  2022-09-05

5.  Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.

Authors:  P Salehi; I Hsu; C G Azen; S D Mittelman; M E Geffner; D Jeandron
Journal:  Pediatr Obes       Date:  2016-04-13       Impact factor: 4.000

Review 6.  Obesity management in Prader-Willi syndrome: current perspectives.

Authors:  Antonino Crinò; Danilo Fintini; Sarah Bocchini; Graziano Grugni
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-04       Impact factor: 3.168

7.  A multidisciplinary approach to the clinical management of Prader-Willi syndrome.

Authors:  Jessica Duis; Pieter J van Wattum; Ann Scheimann; Parisa Salehi; Elly Brokamp; Laura Fairbrother; Anna Childers; Althea Robinson Shelton; Nathan C Bingham; Ashley H Shoemaker; Jennifer L Miller
Journal:  Mol Genet Genomic Med       Date:  2019-01-29       Impact factor: 2.183

8.  Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome.

Authors:  Yoo-Mi Kim; Yeoun Joo Lee; Soo Yeon Kim; Chong Kun Cheon; Han Hyuk Lim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2020-03-31

9.  Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome: A Case Report.

Authors:  Yukio Horikawa; Mayumi Enya; Makie Komagata; Ken-Ichi Hashimoto; Masayo Kagami; Maki Fukami; Jun Takeda
Journal:  Diabetes Ther       Date:  2018-01-15       Impact factor: 2.945

10.  Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity.

Authors:  Marina Caputo; Tommaso Daffara; Simonetta Bellone; Valentina Mancioppi; Paolo Marzullo; Gianluca Aimaretti; Flavia Prodam
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-22       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.